PledPharma AB (publ) Share Price Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
Sales 2024 * | 70.5M 6.51M 520M | Sales 2025 * | 511M 47.15M 3.76B | Capitalization | 1.79B 165M 13.18B |
---|---|---|---|---|---|
Net income 2024 * | -305M -28.16M -2.25B | Net income 2025 * | 175M 16.16M 1.29B | EV / Sales 2024 * | 26.6 x |
Net Debt 2024 * | 87.22M 8.05M 643M | Net cash position 2025 * | 119M 10.98M 877M | EV / Sales 2025 * | 3.27 x |
P/E ratio 2024 * |
-6.43
x | P/E ratio 2025 * |
8.94
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.61% |
Latest transcript on PledPharma AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 15/06/17 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 30/12/17 |
Chief Tech/Sci/R&D Officer | - | 04/05/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mats Blom
CHM | Chairman | 59 | 31/03/21 |
Director/Board Member | 50 | 31/12/19 | |
Thomas Lönngren
BRD | Director/Board Member | 73 | 31/03/21 |
1st Jan change | Capi. | |
---|---|---|
+3.42% | 108B | |
+11.12% | 104B | |
+1.28% | 22.33B | |
-12.68% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-9.63% | 17.64B | |
+4.39% | 14.05B | |
+34.94% | 12.51B |